Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy

1997 ◽  
Vol 8 (4) ◽  
pp. 526-533 ◽  
Author(s):  
E. Janevik-Ivanovska ◽  
E. Gautherot ◽  
M. Hillairet de Boisferon ◽  
M. Cohen ◽  
G. Milhaud ◽  
...  
Keyword(s):  
Iodine 131 ◽  
Pretargeted Radioimmunotherapy

Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer

2019 ◽  
Vol 63 (1) ◽  
Author(s):  
Joji Kawabe ◽  
Shigeaki Higashiyama ◽  
Kohei Kotani ◽  
Atsushi Yoshida ◽  
Naoyoshi Onoda ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Iodine 131

Pancytopenia as a complication of radiotherapy and Iodine 131 treatment in a thyroid cancer

2019 ◽  
Vol 40 (2) ◽  
pp. 89-92 ◽  
Author(s):  
M Herchuelz ◽  
P Bourgeois ◽  
M Aoun
Keyword(s):  
Thyroid Cancer ◽  
Iodine 131

Estudios de dispersión de contaminantes y declinación bacteriana en la bahía del mar de Chimbote - Perú

2016 ◽  
Vol 1 (10) ◽  
Author(s):  
Ing. Carlos Sebastián Calvo
Keyword(s):  
Rhodamine B ◽  
Iodine 131 ◽  
Para Determinar

Una revisión de los estudios de dispersión y una determinación preliminar de T-90 se ha realizado en el mar de Chimbote-Perú. En relación a los estudios de dispersión se presenta una ecuación diferencial fundamental y su solución para el caso de tres dimensiones. La forma y características de la pluma trazadora se definen también como el ratio de disminución de las concentraciones pico. El método considera un punto de inyección con Rhodamine B y Iodine 131 como trazadoras para determinar los coeficientes de dispersión que gobiernas los ratios de dispersión de aguas industriales y desecho a ser descargadas a través de una salida que va a ser instalada en el mar de Chimbote. El método presentado aquí permite el cálculo de los coeficientes de dispersión e influencia del difusor sin importar la naturaleza de la composición del agua en los cuales la prueba se lleva a cabo. Con relación las determinaciones T-90, ellos tuvieron mejor desempeño por el uso de una técnica trazadora combinada, usando el I-131 para la medida de la dilución y Rhodamine B como una ayuda visual. Se tomaron en consideración la dilución y decrecimiento en las concentraciones bacteriales al igual que la inyección continua de radio trazadores. Los valores de T-90 estimados desde los experimentos deberían ser reconfirmados en futuros experimentos bajo condiciones oceanográficas diferentes.

Iodine-131 problems in the 200 areas

1961 ◽  
Author(s):  
G. E. Backman
Keyword(s):  
Iodine 131

Pilot Study of Iodine-131–Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma

2002 ◽  
Vol 20 (8) ◽  
pp. 2142-2149 ◽  
Author(s):  
Gregory A. Yanik ◽  
John E. Levine ◽  
Katherine K. Matthay ◽  
James C. Sisson ◽  
Barry L. Shulkin ◽  
...  
Keyword(s):  
Stem Cell ◽  
Pilot Study ◽  
Neuroblastoma Cells ◽  
Complete Response ◽  
Novel Therapy ◽  
Peripheral Blood Stem Cells ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Myeloablative Chemotherapy ◽  
Iodine 131

PURPOSE: The survival for children with relapsed or metastatic neuroblastoma remains poor. More effective regimens with acceptable toxicity are required to improve prognosis. Iodine-131–metaiodobenzylguanidine (131I-MIBG) selectively targets radiation to catecholamine-producing cells, including neuroblastoma cells. A pilot study was performed to examine the feasibility of a novel regimen combining 131I-MIBG and myeloablative chemotherapy with autologous stem-cell rescue. PATIENTS AND METHODS: Twelve patients with neuroblastoma were treated after relapse (five patients) or after induction therapy (seven patients). Eight patients had metastatic and four had localized disease at the time of therapy. All patients received 131I-MIBG 12 mCi/kg on day −21, followed by carboplatin (1,500 mg/m2), etoposide (800 mg/m2), and melphalan (210 mg/m2) administered from day −7 to day −4. Autologous peripheral-blood stem cells or bone marrow were infused on day 0. Engraftment, toxicity, and response rates were evaluated. RESULTS: The 131I-MIBG infusion and myeloablative chemotherapy were both well tolerated. Grade 2 to 3 oral mucositis was the predominant nonhematopoietic toxicity, occurring in all patients. The median times to neutrophil (≥ 0.5 × 103/μL) and platelet (≥ 20 × 103/μL) engraftment were 10 and 28 days, respectively. For the eight patients treated with metastatic disease, three achieved complete response and two had partial responses by day 100 after transplantation. CONCLUSION: Treatment with 131I-MIBG in combination with myeloablative chemotherapy and hematopoietic stem-cell rescue is feasible with acceptable toxicity. Future study is warranted to examine the efficacy of this novel therapy.

Sign in / Sign up

Export Citation Format

Share Document